Novel human NK3 receptor-selective antagonist compounds, method for obtaining them and pharmaceutical compositions containing them
申请人:——
公开号:US20040220223A1
公开(公告)日:2004-11-04
Compounds of formula (I), a method for obtaining them and pharmaceutical compositions containing them are described. The compounds are useful as human NK
3
receptor antagonists.
11beta-hydroxysteroid dehydrogenase type 1 active spiro compounds
申请人:Kilburn John Paul
公开号:US20090105289A1
公开(公告)日:2009-04-23
A novel class of compounds of the general formula (I), their use in therapy, pharmaceutical compositions comprising the compounds, as well as their use in the manufacture of medicaments are described. The present compounds modulate the activity of 11 β-hydroxy-Steroid dehydrogenase type 1 (11βHSD1) and are accordingly useful in the treatment of diseases in which such a modulation is beneficial, e.g. the metabolic syndrome.
We report herein the synthesis and structure-activity relationships of a series of novel oxazolidine analogues with regards to NK1 and NK2 tachykinin receptor binding affinity. Among this series of oxazolidine analogues, some compounds exhibited excellent high binding affinities for both NK1 and NK2 receptors. In addition, we describe the inhibitory effect in vivo on SP-induced airway vascular hyperpermeability and NKA-induced bronchoconstriction in guinea pigs. (C) 1999 Elsevier Science Ltd. All rights reserved.